Development and preliminary validation of the multiattribute Rhinitis Symptom Utility Index

Quality of Life Research

Volumn 7, Issue 8, 1998, Pages 693-702

  Revicki, D A ^a   Leidy, N K ^a   Brennan Diemer, F ^b   Thompson, C ^a   Togias, A ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

Health preferences; Health related quality of life; Patient outcomes; Rhinitis related symptoms

Indexed keywords

ADULT; ARTICLE; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICIAN; PRIORITY JOURNAL; RHINITIS; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; VALIDATION PROCESS;

ADULT; CROSS-SECTIONAL STUDIES; DATA INTERPRETATION, STATISTICAL; EVALUATION STUDIES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; RHINITIS, ALLERGIC, PERENNIAL; SEVERITY OF ILLNESS INDEX;

EID: 0032453499     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008860113818     Document Type: Article

References (24)

1. Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1991; 21: 77-83.
2. Juniper EF, Guyatt GH, Dolovich J. Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413-423.
3. Juniper EF, Guyatt GH Andersson B, Ferrie PJ. Comparison of a powder and aerolosized budesonide in perennial rhinitis: validation of rhinitis quality of life questionnaire. Ann Allergy 1993; 70: 225-230.
4. Bousquet J, Bullinger M, Fayol C, Marquis P, Valentin B, Burtin B. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 health status questionnaire. J Allergy Clin Immunol 1994; 94: 182-188.
5. Bousquet J, Duchateau J, Pignat JC et al. Improvement of quality of life by treatment with ceririzine in patients with perennial allergic rhinitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996; 98: 309-316.
6. Harvey RP, Comer C, Sanders B et al. Model for outcomes assessment of antihistamine use for seasonal allergic rhinitis. J Allergy Clin Immunol 1996; 97: 1233-1241.
7. de Graaf-in't Veld T, Koenders S, Garrelds IM, Gerth van Wijk R. The relationships between nasal hyperactivity, quality of life and nasal symptoms in patients with perennial allergic rhinitis. J Allergy Clin Immunol 1996; 98: 508-513.
8. Juniper EF, Willms DG, Guyatt GH, Ferrie PJ. Aqueous beclomethasone dipropionate nasal spray in the treatment of seasonal (ragweed) rhinitis. Can Med Assoc J 1992; 147: 887-892.
9. Juniper EF, Guyatt GH, O'Byrne PM, Viveiros M. Aqueous beclomethasone diproprionate nasal spray: regular versus Aas required@ use in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1990; 86: 380-386.
10. Juniper EF, Guyatt GH, Archer B, Ferrie PJ. Aqueous beclomethasone diproprionate in the treatment of ragweed pollen-induced rhinitis: further exploration of 'as needed' use. J Allergy Clin Immunol 1993; 92: 66-72.
11. Georgitis JW, Banov C, Boggs PB et al. Ipratropium bromide nasal spray in non-allergic rhinitis: efficacy, nasal cytological response and patient evaluation on quality of life. Clin Exp Allergy 1994; 24: 1049-1055.
12. Druce HM, Spector SL, Fireman P et al. Double-blind study of intranasal ipratropium bromide in nonallergic perennial rhinitis. Ann Allergy 1992; 69: 53-60.
13. Meltzer EO, Orgel HA, Bronsky EA et al. Ipratroprium bromide aqueous nasal spray for patients with perennial allergic rhinitis: a study of its effect on their symptoms, quality of life and nasal cytology. J Allergy Clin Immunol 1992; 90: 242-249.
14. Revicki DA. Relationship of pharmacoeconomics and health-related quality of life. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 1077-1084.
15. Sculpher MJ, Buxton MJ. The episode-free day as a composite measure of effectiveness: an illustrative economic evaluation of formoterol versus salbutamol in asthma therapy. Pharmacoeconomics, 1993; 4: 345-352.
16. Feeny DH, Torrance GW. Incorporating utility-based quality-of-life assessment measures in clinical trials: two examples. Med Care 1989; 27: S190-S204.
17. Bennett KJ, Torrance GW. Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 253-266.
18. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating Patient Preferences into Health Outcomes: the Multi-attribute Asthma Symptom Utility Index. Chest, in press.
19. Torrance GW, Feeny DH, Furlong W, Barr R, Zhang Y, Wang Q. Multi-attribute preference functions for a comprehensive health status classification system: Health Utilities Index Mark 2. Med Care, 1996; 34: 702-722.
20. Feeny DH, Torrance GW, Furlong W. Health Utilities Index (HUI). In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials, 2nd edn. Philadelphia: Lippincott-Raven, 1996: 239-252.
21. Torrance GW, Boyle MH, Horwood SP. Application of multiattribute utility theory to measure social preferences for health states. Operat Res 1982; 30: 1043-1069.
22. Torrance GW, Furlong W, Feeny DH, Boyle MH. Multiattribute preference functions: Health Utilities Index. Pharmacoeconomics 1995; 7: 503-520.
23. Furlong W, Feeny DH, Torrance GW, Barr R, Horsman J. Guide to Design and Development of Health-state Utility Instrumentation. Hamilton, Ontario: Centre for Health Economics and Policy Analysis, McMaster University, 1990.
24. Hyland ME, Kenyou CAP, Allen R, Howarth P. Diary keeping in asthma: comparison of written and electronic methods. BMJ 1993; 306: 487-489.